DermTech Revenue and Competitors

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. DermTech's Pigmented Lesion Assay (PLA) provides physicians with a non-invasive option to identify clinically atypical pigmented lesions (or moles) at high risk for melanoma. Using an adhesive patch rather than a scalpel, DermTech provides highly accurate, objective information to the physician to improve patient care and comfort through advanced molecular pathology gene expression. The PLA is intended for use on pigmented skin lesions, which are clinically suspicious for melanoma. These lesions may meet one or more ABCDE criteria. The diagnosis of early stage melanoma is inaccurate by visual assessment and histopathologic slide review. The false negative diagnosis for melanoma in-situ/Stage 1 a melanoma was found to be 35% in a recent large scale study of pathologists in the US. By comparison, the PLA has a negative predictive value of 99% and significantly reduces the number needed to biopsy.